Cambrian Capital Partners

CND Life Sciences specializes in developing diagnostic tools for neurodegenerative diseases, particularly focusing on synucleinopathy. The company has introduced the Syn-One Test, which is designed to detect, visualize, and quantify abnormal phosphorylated alpha-synuclein in cutaneous nerve fibers. This commercially available test serves as an objective diagnostic aid for confirming synucleinopathy in patients suspected of having conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or pure autonomic failure. By providing a convenient and minimally invasive method for diagnosis, CND Life Sciences enhances the ability of medical professionals to accurately identify these complex disorders.

CND Life Sciences specializes in developing diagnostic tools for neurodegenerative diseases, particularly focusing on synucleinopathy. The company has introduced the Syn-One Test, which is designed to detect, visualize, and quantify abnormal phosphorylated alpha-synuclein in cutaneous nerve fibers. This commercially available test serves as an objective diagnostic aid for confirming synucleinopathy in patients suspected of having conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or pure autonomic failure. By providing a convenient and minimally invasive method for diagnosis, CND Life Sciences enhances the ability of medical professionals to accurately identify these complex disorders.